Equibles does not estimate personal net worth.
Get an email with a short summary when Travere Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TVTX alertsTravere Therapeutics, Inc. reported in an 8-K filed June 16, 2026 that Jula Inrig was appointed Executive Vice President, Head of Research & Development and Chief Medical Officer, effective July 1, 2026. The proxy statement of Travere Therapeutics, Inc. reports total compensation of $3,041,632 for Jula Inrig in fiscal 2025, including a base salary of $568,084. Disclosed compensation is on record for 4 fiscal years. Jula Inrig has spoken on 3 earnings calls and 1 other investor event across 1 company, most recently for Travere Therapeutics, Inc. on August 4, 2026. Travere Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Travere Therapeutics, Inc. includes Bradley Campbell (CEO and Board Member), Bradley L. Campbell (CEO and Board Member), Christopher Cline (CFO) and 7 others.
“Effective July 1, 2026, Dr. Inrig is being named Executive Vice President, Head of Research & Development and Chief Medical Officer.”
“I'll start with Phil Spari, the only approved therapy that can replace RAS inhibitors while directly addressing key drivers of ongoing kidney injury.”
“I'm very excited to have the first ever approved medicine for the FSGS community now available for patients. As a reminder, Filspari was approved to reduce proteinuria in adults and children eight years and older with FSGS without nephrotic syndrome.”
“As a nephrologist who treated patients with FSGS for decades, today's approval represents an incredible advancement for the field, and most importantly, for patients who until today had no approved medicine.”
“I'll start by highlighting our continued efforts to support the awareness and education of the FILSPARI clinical profile. As Eric mentioned earlier, we were very pleased with the recent publication of the interim results from the Phase 3 PROTECT study in the Lancet.”
Proxy statement
Start not stated–present
Last confirmed April 6, 2026
Biotechnology · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Travere Therapeutics, Inc. (TVTX) | Chief Medical Officer | $568,084 | $3,041,632 |
| 2024 | Travere Therapeutics, Inc. (TVTX) | Chief Medical Officer | $522,083 | $1,681,277 |
| 2023 | Travere Therapeutics, Inc. (TVTX) | Chief Medical Officer | $486,250 | $2,001,539 |
| 2022 | Travere Therapeutics, Inc. (TVTX) | Chief Medical Officer | $445,000 | $2,866,793 |
